Cargando…
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications—including bleeding and potential drug–drug interactions with chemotherapy—associated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagula...
Autores principales: | Ay, C, Beyer-Westendorf, J, Pabinger, I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594460/ https://www.ncbi.nlm.nih.gov/pubmed/30918939 http://dx.doi.org/10.1093/annonc/mdz111 |
Ejemplares similares
-
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016) -
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017) -
Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014) -
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019) -
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)